NP
CHRONICLES
Clinical Education for NP Students & New Graduates
The
First CKM Syndrome Guidelines: What NPs Need to Know
Cardiometabolic
Health |
Board Prep | Chronic Disease Management
If “CKM syndrome” isn't yet part
of your everyday vocabulary, it's about to be. Three years after the American
Heart Association first defined cardiovascular-kidney-metabolic (CKM) syndrome
as a unifying framework, an interdisciplinary coalition — the AHA, American
College of Cardiology (ACC), American Society of Nephrology, and the American
Diabetes Association's Obesity Alliance — has released the first clinical
guidelines to operationalize it. Reporting by Jennifer Abbasi in JAMA Medical
News lays out what primary care clinicians need to know, and for NPs, this is
about as bread-and-butter as guideline updates get.
These guidelines replace the
AHA/ACC/Obesity Society obesity guidance from 2013 — more than a decade old —
and reflect a fundamental reframing: obesity, diabetes, chronic kidney disease,
and cardiovascular disease aren't separate problems that happen to co-occur.
They're staged, interrelated expressions of the same underlying process, and
treating them as isolated silos is part of why cardiovascular mortality has
plateaued after decades of decline.
Why This Framework Exists
Chiadi E. Ndumele, MD, PhD, MHS,
chair of the guideline writing committee and director of obesity and
cardiometabolic research at Johns Hopkins, explained the epidemiologic logic:
as obesity prevalence has climbed, metabolically active visceral fat has driven
up the number of patients with overlapping diabetes, CKD, and cardiovascular
risk factors — a convergence that's now measurably slowing progress against
cardiovascular death. “These multisystem consequences of obesity are now
catching up to us,” Ndumele said.
Sadiya S. Khan, MD, MSc, of
Northwestern, who serves on the ACC/AHA guidelines committee, framed the
guideline's purpose simply: “The idea behind the guideline is to really try to
break down those silos... it's all of our responsibility, and every touchpoint
matters.”
Know the Five Stages
CKM staging is designed to
function as a roadmap for prevention, not just a snapshot of current disease.
Ndumele called each stage a “window of opportunity for preventive action.”
|
Stage |
Defining Criteria |
|
Stage 0 |
No CKM risk factors: normal
BMI/waist circumference, blood glucose, blood pressure, lipids; no CKD or CVD |
|
Stage 1 |
Excess or dysfunctional
adiposity: overweight/obesity, abdominal obesity, or dysfunctional adipose
tissue (elevated fasting glucose or A1c), without other metabolic risk
factors or CKD |
|
Stage 2 |
Metabolic risk factors, CKD,
or both: hypertension, hypertriglyceridemia, metabolic syndrome, or type 2
diabetes; moderate-to-high risk CKD per KDIGO |
|
Stage 3 |
Subclinical CVD in CKM:
subclinical coronary atherosclerosis (coronary artery calcium) or pre-heart
failure (elevated biomarkers/echo findings); OR very high-risk CKD; OR
predicted 10-yr PREVENT-CVD risk ≥20% |
|
Stage 4 |
Clinical CVD in CKM: coronary
heart disease, heart failure, stroke, peripheral artery disease, or atrial
fibrillation, alongside adiposity, other CKM risk factors, or CKD |
Screening: Go Beyond BMI
The guidelines frame obesity as
an upstream driver of illness, not a cosmetic concern, and they call for annual
assessment of all patients using both BMI and waist circumference — because
abdominal adiposity specifically carries much of the metabolic risk.
•
Abdominal
obesity thresholds: waist circumference ≥88 cm in women, ≥102 cm in men (lower
thresholds apply for people of Asian ancestry).
•
The
guidelines emphasize nonjudgmental, clinician-initiated weight conversations
rather than waiting for patients to raise the topic. Ndumele: “How we talk
about obesity, how we engage in the obesity discussion, dramatically impacts
how successful we are with regards to weight-loss efforts.”
•
First-line
treatment remains lifestyle modification targeting 5–10% weight reduction, with
pharmacotherapy and, when appropriate, metabolic/bariatric surgery layered in
as needed — not reserved as a last resort.
Don't Skip the Kidney Screening
Kidney disease is one of the
guideline's central emphases, and for good reason: CKD is frequently
asymptomatic until advanced stages, yet it's now treatable earlier and more
effectively than in years past. Khan called kidney disease recognition one of
the guideline's “most important takeaways.”
•
All
adults should be regularly tested using estimated glomerular filtration rate
(eGFR).
•
Patients
at Stage 2 CKM or higher should also be regularly tested using urine
albumin-to-creatinine ratio (UACR).
•
Albuminuria
is treated as a modifiable risk factor, similar to blood pressure. Per
Katherine R. Tuttle, MD: “If albuminuria is high, we will continue to intensify
therapy to reduce it. So it's treatable and it's modifiable.”
On the pharmacologic side, the
guidelines highlight therapies with benefit across multiple CKM domains
simultaneously — GLP-1 receptor agonists, SGLT2 inhibitors, and nonsteroidal
mineralocorticoid receptor antagonists — as tools that can address adiposity,
glycemic control, kidney protection, and cardiovascular risk together rather
than requiring separate agents for each.
The PREVENT Equations: Numbers
Worth Knowing
The PREVENT risk calculator has
replaced the pooled cohort equations and is now central to CKM staging and
treatment decisions. Unlike its predecessor, PREVENT incorporates BMI and eGFR
directly, and allows clinicians to add UACR, hemoglobin A1c, and social
deprivation index as optional predictors for a more individualized estimate.
|
Threshold |
Clinical Significance |
|
10-yr PREVENT-CVD risk ≥20% |
Classifies patient as Stage 3
CKM |
|
10-yr PREVENT-CVD risk ≥7.5% |
Can inform initiating GLP-1
therapy, an SGLT2 inhibitor, or both |
|
10-yr PREVENT-HF risk ≥5% |
Can trigger cardiac biomarker
evaluation for pre-heart failure and additional diagnostic workup |
Khan noted a useful new feature:
the calculator now reports a patient's percentile for 30-year cardiovascular
risk relative to peers of the same age and sex — she compared it to a pediatric
growth chart, a framing that may help patients contextualize their own risk
more concretely than a raw percentage.
|
CLINICAL BOTTOM LINE CKM syndrome guidelines
formalize what many NPs already sense clinically: obesity, diabetes, CKD, and
cardiovascular disease are staged expressions of one interconnected process,
not separate diagnoses to manage in isolation. Key actions: assess BMI and waist
circumference annually in all patients, screen kidney function with eGFR (and
UACR for Stage 2+), use the PREVENT equations to guide staging and treatment
thresholds, and favor therapies (GLP-1 RAs, SGLT2 inhibitors, nonsteroidal
MRAs) with benefit across multiple CKM domains when clinically appropriate. |
Team-Based Care — and Where NPs
Fit
The guidelines explicitly call
for interdisciplinary, team-based care, including a dedicated care coordinator
role for patients with overlapping CKM conditions. Notably, Ndumele
specifically named nurses — alongside diabetes educators, heart failure case
coordinators, and pharmacists — as well-positioned to fill that coordinating
role, rather than assuming it must fall to a physician subspecialist.
“We have primary care physicians
on our group,” Ndumele said of the guideline committee, “and we're very
conscious about just dropping a bunch more responsibilities in the lap of
people who already have a lot on their plate.” The guidelines also call for
evaluating and addressing adverse social determinants of health as part of
holistic CKM care — not a separate initiative layered on top.
|
NUANCE TO FLAG These are inaugural guidelines
for a framework that's only three years old, consolidating recommendations
that were previously scattered across separate obesity, diabetes, kidney, and
cardiovascular guidance. Expect refinement as more outcomes data accumulates
on staged, cross-domain management — particularly around how aggressively to
intervene at Stage 1 (adiposity alone, before other risk factors appear)
versus waiting for Stage 2 criteria to be met. As with any new staging
system, documentation and coding practices in your setting may lag behind the
clinical framework; check with your practice on how CKM staging is expected
to integrate with existing problem lists and billing before assuming it's a
drop-in replacement for existing obesity or CKD documentation. |
Why This Matters for Your Panel
Katherine R. Tuttle, MD, put it
plainly: she hopes the guidelines become “the bread and butter” of internal
medicine practice, since most patients seen in general internal medicine will
have at least one CKM risk factor. The same is true, arguably even more so, for
NPs in primary care, where the volume of patients with overweight, prediabetes,
hypertension, or early kidney changes is high and the opportunity to intervene
at Stage 1 or 2 — before subclinical or clinical cardiovascular disease
develops — is squarely a primary care function.
For board review purposes, the
staging criteria, the PREVENT risk thresholds, and the annual BMI/waist
circumference screening recommendation are all high-yield material likely to
show up in cardiometabolic and endocrine content going forward. Familiarity
with the eGFR/UACR testing cadence by stage is equally worth committing to
memory, since kidney screening remains one of the more commonly missed pieces
of routine chronic disease management.
Reference
Abbasi, J. (2026, July 17). What
to know about the first CKM syndrome guidelines. JAMA.
doi:10.1001/jama.2026.12081
